Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Invitrogen has entered into an exclusive license agreement with IMBcom Proprietary Limited Company to commercialize new non-coding ribonucleic acid content, predicted by a proprietary algorithm and experimentally validated by the University of Queensland, Australia.
Subscribe to our email newsletter
Invitrogen will commercialize these sequences over the next few years, allowing the company to expand its NCode microRNA microarray product line into the field of non-coding RNA profiling. This expanded content will enable Invitrogen to provide the most comprehensive non-coding RNA product portfolio in the market and be the first company to provide this new content to the research community.
Peter Welch, director of research and development for gene expression profiling at Invitrogen, said: “MicroRNAs have a discrete function in gene regulation, but the larger non-coding RNAs are involved in multiple roles such as cellular aging and protein assembly, in addition to simple gene regulation.”